Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session: NETs and endocrine tumours

887O - First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with <sup>177</sup>Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial

Date

12 Sep 2022

Session

Proffered Paper session: NETs and endocrine tumours

Topics

Radiation Oncology

Tumour Site

Neuroendocrine Tumours

Presenters

Eric Baudin

Citation

Annals of Oncology (2022) 33 (suppl_7): S410-S416. 10.1016/annonc/annonc1060

Authors

E. Baudin1, T.A. Walter2, A. Beron3, D. Smith4, J. Hadoux5, C. Lachachi6, D. Taieb7, C. Ansquer8, L.O. Dierickx9, L. de Mestier du Bourg10, E. Deshayes11, E. quak12, L. Dahan13, R. Guimbaud14, Y. Touchefeu15, M. Haissaguerre16, C. DO CAO17, C. Lombard Bohas18, M. Attard19, S. Foulon20

Author affiliations

  • 1 Imaging Endocrine Unit, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 2 Medical Oncology, Hospices Civiles de Lyon - HCL - Lyon University Hospital Center, 69002 - Lyon/FR
  • 3 Nuclear Medicine, CHU Lille - Hopital Claude Huriez, 59037 - Lille/FR
  • 4 Digestive Oncology, Hopital Haut Leveque, 33000 - Pessac/FR
  • 5 Endocrine Oncology Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 6 Nuclear Medicine, Hospices Civils de Lyon, 69500 - Bron/FR
  • 7 Nuclear Medicine, CHU de Marseille - Hôpital de la Timone, 13385 - Marseille/FR
  • 8 Nuclear Medicine, Chu Nantes Hotel Dieu, 44000 - Nantes/FR
  • 9 Nuclear Medicine, Institut Claudius Regaud, 31059 - Toulouse/FR
  • 10 Gastroenterology - Pancreatology, Beaujon Hospital APHP, 92110 - Clichy/FR
  • 11 Nuclear Medicine, ICM - Institut régional du Cancer de Montpellier, Val d'Aurelle, 34298 - Montpellier, Cedex /FR
  • 12 Nuclear Medicine, Centre François Baclesse, Caen/FR
  • 13 Digestive Oncology, AP-HM - CHU La Timone Enfants, 13385 - Marseille/FR
  • 14 Digestive Medical Oncology Unit, Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, 31059 - Toulouse/FR
  • 15 Digestive Oncology, CHU du Nantes - Hôtel-Dieu, 44093 - Nantes, Cedex/FR
  • 16 Endocrine Oncology Department, CHU de Bordeaux-Hôpital Haut-Lévêque, 33604 - Pessac/FR
  • 17 Endocrinology, Centre Hospitalier Régional Universitaire de Lille, 59000 - Lille/FR
  • 18 Digestive Oncology, Hopital Edouard Herriot Pav. E bis, 69437 - Lyon/FR
  • 19 Ile De France, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 20 Biostatistics And Epidemiology Office, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
More

Resources

Login to access the resources on OncologyPRO.

Abstract 887O

Background

No randomized trial has investigated the role of peptide receptor radionucleide therapy (PRRT) in advanced PanNET patients. We report the results of the first multicentric randomized open-label phase II study assessing PRRT-177Lutetium-Octreotate antitumor efficacy.

Methods

Patients (pts) with somatostatin receptor scintigraphy positive progressive advanced PanNET within 1 year according to RECIST1.1 were randomized 1:1 to OCLU (7.4 GBqX4/8w) or sunitinib (SUN;37.5 mg/d ) and stratified for prognostic factors.Primary endpoint was: progression-free survival (PFS) rate at 12 months according to RECIST 1.1 real-time central review. Secondary endpoints were : tumour response, PFS, overall survival, safety (NCI CTCAE v.4). The sample size calculation of the OCLU arm assumed a 25% increase (from 35% to 60%) of the 12-m PFS rate. 40 pts had to be included in a single stage Fleming design with type I error = type II error = 5%. If 19 or more pts showed no progression or death at 12 months, OCLU would be considered effective (Fleming design conclusion). The SUN group served as an internal control to validate the hypothesis of the Fleming design with a 12 months PFS rate of 35%.

Results

84 pts were enrolled (41 OCLU arm , 43 SUN arm ;median age, 63 yrs,52% female). Main characteristics were:Ki67>10%, 37% pts; >25% liver involvement,42% pts; functioning syndrome, 20% pts ; ≥2 systemic lines, 43% , well balanced between each arm. The primary endpoint was met with a 12m-PFS rate at 80.5% (33/41 pts with 12m-PFS) in the OCLU arm (IC90%: 67.5-89.9) vs. 42 % in the SUN arm (n=18/43 pts with 12mPFS) (IC90%: 29.1-55.5,including 35%). Median PFS was 20.7 in the OCLU arm (90CI: 17.2-23.7) vs. 11 months in the SUN arm (90CI:8.8-12.4). 44% pts with OCLU vs. 60% with SUN experienced grade 3-4 adverse events, with fatigue (7% vs. 12%), decrease blood count (12% vs 24%) and hypertension (12% vs. 19%) among the most frequent. One death occurs in the SUN arm. Additional results will be presented (best response, updated adverse events and, subgroup analysis).

Conclusions

The OCLURANDOM trial met is primary endpoint.

Clinical trial identification

EudraCT 2013-004032-30.

Editorial acknowledgement

Legal entity responsible for the study

Gustave Roussy.

Funding

French Academic Projet Hospitalier Recherche Clinique (PHRC) grant and AAA/Novartis Pharma.

Disclosure

E. Baudin: Financial Interests, Institutional, Advisory Board, Advisory board and principal investigator: Novartis; Financial Interests, Institutional, Advisory Board: HRA, Hutchinson Pharma; Financial Interests, Personal, Other, Project lead and principal investigator: Ipsen; Financial Interests, Institutional, Other: Pfizer; Financial Interests, Personal, Advisory Board: Novartis - AAA; Financial Interests, Institutional, Research Grant: Novartis, HRA, Pfizer; Non-Financial Interests, Principal Investigator: Enterome; Non-Financial Interests, Advisory Role: Hutchinson Pharma; Non-Financial Interests, Leadership Role: Endocan Network. T.A. Walter: Financial Interests, Personal, Advisory Role: Novartis-AAA, Keocyt; Non-Financial Interests, Personal, Funding: Ipsen; Non-Financial Interests, Institutional, Project Lead: ROCHE. J. Hadoux: Financial Interests, Personal, Advisory Board: Ipsen, Lilly, Pharma Mar; Financial Interests, Institutional, Invited Speaker: AAA, Pfizer. C. Lachachi: Financial Interests, Institutional, Advisory Board: Novartis-AAA. D. Taieb: Financial Interests, Personal, Advisory Board: Novartis-AAA; Financial Interests, Personal, Invited Speaker: Novartis-AAA; Financial Interests, Institutional, Principal Investigator: Ipsen, Novartis-AAA. C. Ansquer: Financial Interests, Personal, Advisory Board: Novartis-AAA; Financial Interests, Personal, Invited Speaker: Novartis-AAA. L. de Mestier du Bourg: Financial Interests, Personal, Advisory Role: AAA, Ipsen, Keocyt, SIRTex. E. Deshayes: Financial Interests, Personal, Invited Speaker: Novartis-AAA. L. Dahan: Financial Interests, Personal, Invited Speaker: Servier, Novartis-AAA, Pierre Fabre, Oseus. Y. Touchefeu: Financial Interests, Personal, Invited Speaker: Novartis-AAA. C. Lombard Bohas: Financial Interests, Personal, Advisory Board: Novartis-AAA; Financial Interests, Institutional, Principal Investigator: Ipsen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.